These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. Normal tissue architecture determines the evolutionary course of cancer. West J; Schenck RO; Gatenbee C; Robertson-Tessi M; Anderson ARA Nat Commun; 2021 Apr; 12(1):2060. PubMed ID: 33824323 [TBL] [Abstract][Full Text] [Related]
85. A modelling framework for cancer ecology and evolution. Adler FR J R Soc Interface; 2024 Jul; 21(216):20240099. PubMed ID: 39013418 [TBL] [Abstract][Full Text] [Related]
87. A Countable-Type Branching Process Model for the Tug-of-War Cancer Cell Dynamics. Wang RY; Kimmel M Bull Math Biol; 2024 Jan; 86(2):18. PubMed ID: 38236346 [TBL] [Abstract][Full Text] [Related]
88. Molecular tumour clocks. Shibata D Ann Med; 1997 Feb; 29(1):5-7. PubMed ID: 9073319 [TBL] [Abstract][Full Text] [Related]
89. Modes of Selection in Tumors as Reflected by Two Mathematical Models and Site Frequency Spectra. Kurpas MK; Kimmel M Front Ecol Evol; 2022; 10():. PubMed ID: 37333691 [TBL] [Abstract][Full Text] [Related]
90. Temporal order of mutations influences cancer initiation dynamics. Teimouri H; Kolomeisky AB Phys Biol; 2021 Jul; 18(5):. PubMed ID: 34130273 [TBL] [Abstract][Full Text] [Related]
91. Innovation in viruses: fitness valley crossing, neutral landscapes, or just duplications? Banse P; Elena SF; Beslon G Virus Evol; 2024; 10(1):veae078. PubMed ID: 39386076 [TBL] [Abstract][Full Text] [Related]
92. Tumor diversity and the trade-off between universal cancer tasks. Hausser J; Szekely P; Bar N; Zimmer A; Sheftel H; Caldas C; Alon U Nat Commun; 2019 Nov; 10(1):5423. PubMed ID: 31780652 [TBL] [Abstract][Full Text] [Related]
93. Neutral evolution of rare cancer mutations in the computer and the clinic. Beckman RA NPJ Syst Biol Appl; 2024 Oct; 10(1):110. PubMed ID: 39358357 [TBL] [Abstract][Full Text] [Related]
94. Optimal pathways control fixation of multiple mutations during cancer initiation. Teimouri H; Spaulding C; Kolomeisky AB Biophys J; 2022 Oct; 121(19):3698-3705. PubMed ID: 35568975 [TBL] [Abstract][Full Text] [Related]
95. Quantification of the Selective Advantage of Driver Mutations Is Dependent on the Underlying Model and Stage of Tumor Evolution. Bozic I Cancer Res; 2022 Jan; 82(1):21-24. PubMed ID: 34983781 [TBL] [Abstract][Full Text] [Related]
96. Loss of Tumor Suppressor Genes Is Enriched by the Adaptive Immune System. Cancer Discov; 2021 Dec; 11(12):OF6. PubMed ID: 34598940 [TBL] [Abstract][Full Text] [Related]
97. Emergent properties of a computational model of tumour growth. Pantziarka P PeerJ; 2016; 4():e2176. PubMed ID: 27413638 [TBL] [Abstract][Full Text] [Related]
98. "Paradoxical neoantigenic mutations": not simply a driver vs passenger dualism. Meng XY Br J Cancer; 2023 Jul; 129(1):1-2. PubMed ID: 37069345 [No Abstract] [Full Text] [Related]
99. Spatial simulation of autologous cell defection for cancer treatment. Choi J Evol Med Public Health; 2023; 11(1):461-471. PubMed ID: 38111808 [TBL] [Abstract][Full Text] [Related]
100. Cancer (r)evolution. von Loga K; Gerlinger M Nat Ecol Evol; 2017 Aug; 1(8):1051-1052. PubMed ID: 29046586 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]